Detailed Narrative
Strong FY25 Performance Driven by Derivatives & Specialty
Epigral Limited achieved its highest ever revenue of ₹2565 crores and PAT of ₹357 crores in FY25, marking a 33% growth in revenue and an 82% growth in PAT compared to FY24. This robust performance was largely attributed to the Derivatives & Specialty business, which increased its revenue contribution to 54% in FY25 from 45% in the previous year. The company also reported a 48% growth in EBITDA to ₹711 crores, with the EBITDA margin expanding to 28% from 25% in FY24, reflecting the success of its diversification strategy into higher-value products.
Capacity Expansion and Commercialization Progress
The company has commissioned new chlorotoluene, CPVC, and CPVC compound plants, which are currently ramping up and are expected to reach optimal utilization by December/January of FY26. Epigral plans to spend approximately ₹450 crores on CAPEX in FY26, primarily for expanding CPVC resin capacity to 1,50,000 tonnes and Epichlorohydrin capacity from 50,000 to 1,00,000 tonnes by the first half of FY27. These expansions are projected to drive a volume growth of 10-15% in FY26 and maintain a CAGR of 10-15% over the next five years.
Improved Financial Health and Credit Rating
Epigral significantly strengthened its balance sheet, with the net debt-to-EBITDA ratio improving remarkably to 0.7x at the end of March 2025, down from 2.0x a year prior. This improvement is a result of debt reduction and increased profitability. The company's Return on Capital Employed (ROCE) also improved to 25% for FY25 (17% in FY24), reaching 28% when excluding capital work-in-progress. This financial stability was recognized by CRISIL, which upgraded Epigral's rating to AA Stable from AA- positive outlook.
Market Dynamics and Product Realizations
While the company's overall performance was strong, some product segments faced headwinds. Hydrogen peroxide realizations dropped in Q4 FY25, and CPVC pricing is anticipated to be on a downward trend in the next couple of quarters due to slower demand growth and lower global PVC prices. Conversely, ECH pricing is expected to be slightly higher. Management noted that global caustic soda prices remain soft due to low demand from downstream chemistry, but strong demand from alumina and nickel mining helps maintain firmness.
Future Strategy: New Chemistry and Operational Efficiency
Epigral is actively exploring new chemistry value chains for a new 100-acre location, with plans to be disclosed upon Board approval, aiming for long-term growth and further diversification. The company also expects improved operational efficiency from its caustic soda plant starting next quarter, following a major membrane and electrolysis change completed in May. The long-term average EBITDA margin target remains at 25%, supported by the strategic shift towards high-value products and integrated operations.